In the News
The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs
 
Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...
Site Search

>> Advanced Search

Free Newsletter

  Email address:
   

Sinobiomed, Needing a Turnaround, Replaces Entire Management Team

publication date: Feb 18, 2009
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Sinobiomed Inc. has replaced its entire management team with people who have both venture capital and industry experience. Sinobiomed is up against the ropes financially – it has no cash and little in the way of revenues. It talks about its ten recombinant products – three on the market, four in clinical trials and three in research and development – but with only $347,000 in cash, just $827,000 in revenues (for nine months), and a net loss of $4.1 million (also for nine months), the company must do something quickly. It is looking at a working capital deficiency of $14.3 million. More details...

Stock Symbol: (OTCBB: SOBM)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...


Login

 

 
   
ChinaBio® Events
BioBay Investor Forum 2010
Suzhou, China
November 3 - 4, 2010
China Forum 2010
Munich, Germany
November 14, 2010

 
ChinaBio® Investor Forum 2010 - Guangzhou
Guangzhou, China
December 21, 2010
Partner Events
BioPharm America™ 2010
Boston, MA, USA
September 15–17, 2010

CALAsia 2010
San Diego, USA
October 4-5, 2010

CHINA PRETRIALS 2010: Global Preclinical Development Summit
Beijing, China
October 17-19, 2010

CHINA TRIALS 2010
Beijing, China
November 7-9, 2010

12th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM)
Beijing, China
November 9-11, 2010
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners